These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11396280)

  • 21. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.
    Craig WA
    Scand J Infect Dis Suppl; 1993; 91():33-40. PubMed ID: 8290901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.
    Wallis SC; Mullany DV; Lipman J; Rickard CM; Daley PJ
    Intensive Care Med; 2001 Apr; 27(4):665-72. PubMed ID: 11398692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High extracellular levels of cefpirome in unaffected and infected lung tissue of patients.
    Lindenmann J; Kugler SA; Matzi V; Porubsky C; Maier A; Dittrich P; Graninger W; Smolle-Jüttner FM; Joukhadar C
    J Antimicrob Chemother; 2011 Jan; 66(1):160-4. PubMed ID: 21081546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Study of Intravenous Acetaminophen Administered to Critically Ill Multiple-Trauma Patients at the Usual Dosage and a New Proposal for Administration.
    Fuster-Lluch O; Zapater-Hernández P; Gerónimo-Pardo M
    J Clin Pharmacol; 2017 Oct; 57(10):1345-1352. PubMed ID: 28419483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
    Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
    Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Boereboom FT; Ververs FF; Blankestijn PJ; Savelkoul TJ; van Dijk A
    Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.
    Kang S; Jang JY; Hahn J; Kim D; Lee JY; Min KL; Yang S; Wi J; Chang MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
    Badian M; Malerczyk V; Collins JD; Dixon GT; Verho M; Eckert HG
    Chemotherapy; 1988; 34(5):367-73. PubMed ID: 3180904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.
    Isert D; Klesel N; Limbert M; Markus A; Seibert G; Schrinner E
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():31-7. PubMed ID: 1601754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.